Raymond James Has Lowered Expectations for DRI Healthcare Trust (TSE:DHT.UN) Stock Price

DRI Healthcare Trust (TSE:DHT.UN) had its target price reduced by Raymond James from C$23.00 to C$22.00 in a research report report published on Wednesday morning,BayStreet.CA reports.

Several other research firms have also recently weighed in on DHT.UN. Scotiabank boosted their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Truist Financial reduced their price objective on shares of DRI Healthcare Trust from C$17.00 to C$14.00 in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of C$18.00.

DRI Healthcare Trust Price Performance

DHT.UN stock opened at C$12.94 on Wednesday. The firm has a 50-day moving average price of C$13.32 and a 200-day moving average price of C$13.59. DRI Healthcare Trust has a 12 month low of C$10.39 and a 12 month high of C$17.43.

DRI Healthcare Trust Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, October 18th were issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date of this dividend was Friday, September 27th. DRI Healthcare Trust’s dividend payout ratio is currently -920.00%.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.